Mỹ Dang is currently the Director of Regulatory Affairs for Innomar Strategies, a division of Cencora. She has over 25 years of experience in the healthcare sector, and experNse in regulatory affairs and quality assurance. She has previously worked in regulatory affairs for Boehringer Ingelheim (Canada) Ltd., Lundbeck Canada and Knight TherapeuNcs Inc. She has a comprehensive understanding of the drug development process for immunotherapy, from concepNon to market authorizaNon and life cycle management. Mÿ was a facilitator and member of the program advisory commiTee for Algonquin College. She is a member of the Board of the Canadian AssociaNon of Professionals in Regulatory Affairs (CAPRA) and a member of the Programming CommiTee for the Drug InformaNon AssociaNon (DIA).